Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2 ‐negative early breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor‐stroma ratio is associated with
Miller‐Payne
score and pathological response to neoadjuvant chemotherapy in
HER2
‐negative early breast cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 149, Issue 5, Pages 1181-1188
Publisher
Wiley
Online
2021-05-28
DOI
10.1002/ijc.33700
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer
- (2020) Kiki M.H. Vangangelt et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
- (2020) Stefanie de Groot et al. Nature Communications
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
- (2018) Waqar Haque et al. BREAST CANCER RESEARCH AND TREATMENT
- The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients
- (2018) K.M.H. Vangangelt et al. INTERNATIONAL JOURNAL OF CANCER
- Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
- (2018) G. W. van Pelt et al. VIRCHOWS ARCHIV
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
- (2018) C. J. H. Kramer et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit
- (2018) Pauline E.R. Spronk et al. EJSO
- Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers
- (2018) Wenyong Tan et al. Cancer Management and Research
- Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial
- (2016) Matthew D. Hale et al. Oncotarget
- Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial
- (2015) T.J.A. Dekker et al. Molecular Oncology
- Microenvironmental regulation of therapeutic response in cancer
- (2015) Florian Klemm et al. TRENDS IN CELL BIOLOGY
- Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
- (2013) T. J. A. Dekker et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- The prognostic value of tumour-stroma ratio in triple-negative breast cancer
- (2012) A.M. Moorman et al. EJSO
- Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer
- (2012) Yonghui Wu et al. GUT
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients
- (2010) Esther M. de Kruijf et al. BREAST CANCER RESEARCH AND TREATMENT
- Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies
- (2010) Ewout F.W. Courrech Staal et al. EUROPEAN JOURNAL OF CANCER
- Hallmarks of cancer: Interactions with the tumor stroma
- (2010) Kristian Pietras et al. EXPERIMENTAL CELL RESEARCH
- A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
- (2009) Pierre Farmer et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search